HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD: Anti-Aging Claims ‘Muted A Bit,’ But Vigilance Remains High

This article was originally published in The Rose Sheet

Executive Summary

Anti-aging claims in the cosmetics sector show improved compliance with advertising standards overall, but the National Advertising Division remains on the lookout for potential overstatements, particularly as personal-care companies are less inclined to challenge each other than players in other industries.

You may also be interested in...



FDA Clampdown On Excessive Anti-Aging Claims May Lighten Up In 2017

FDA issued close to 30 warning letters to cosmetics firms in 2016 for unapproved drug claims as part of “a project for reviewing product labels and websites for drug claims related to anti-aging.” That initiative may be winding down, if it hasn’t already, but the agency is playing its cards close to its vest going into the new year.

CRN Support For NAD At 10 Years: 250 Ad Claim Reviews, Better Industry Image

"We hoped that it would have legs and it would last," says CRN President and CEO Steve Mister. "We thought, 'If it makes a difference, if we feel like we actually are doing something of value for the industry, we'll keep it up'."

FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era

Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel